Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee, Kyung-Hun

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. [electronic resource] - BMC cancer Apr 2007 - 63 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1471-2407

10.1186/1471-2407-7-63 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor
Breast Neoplasms--chemistry
Chemotherapy, Adjuvant
Cohort Studies
Combined Modality Therapy
Cyclophosphamide--administration & dosage
Disease-Free Survival
Doxorubicin--administration & dosage
Drug Administration Schedule
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Genes, bcl-2
Humans
Ki-67 Antigen--analysis
Lymph Node Excision
Mastectomy, Modified Radical
Mastectomy, Segmental
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neoplasm Staging
Paclitaxel--administration & dosage
Prognosis
Proto-Oncogene Proteins c-bcl-2--analysis
Radiotherapy, Adjuvant
Receptor, ErbB-2--analysis
Receptors, Estrogen--analysis
Receptors, Progesterone--analysis
Survival Analysis
Tamoxifen--administration & dosage
Tumor Suppressor Protein p53--analysis